Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.1% – Should You Sell?

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) fell 4.1% during trading on Tuesday . The company traded as low as $12.56 and last traded at $12.56. 42,943 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 762,696 shares. The stock had previously closed at $13.10.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $20.83.

Stoke Therapeutics Stock Up 1.5 %

The stock’s fifty day simple moving average is $13.24 and its two-hundred day simple moving average is $13.70. The firm has a market cap of $697.59 million, a PE ratio of -6.08 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently bought and sold shares of the business. Quest Partners LLC bought a new stake in shares of Stoke Therapeutics in the second quarter worth approximately $29,000. Nisa Investment Advisors LLC lifted its holdings in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after buying an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics in the 2nd quarter worth $123,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Stoke Therapeutics in the first quarter worth $141,000. Finally, The Manufacturers Life Insurance Company increased its position in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.